Skip to main content

Advertisement

Open Peer Review Reports for: Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study

Back to article

Pre-publication versions of this article are available by contacting info@biomedcentral.com.

Original Submission
12 Jul 2010 Submitted Original manuscript
26 Jul 2010 Reviewed Reviewer Report - Jozelio Carvalho
17 Aug 2010 Reviewed Reviewer Report - Cemalettin Aybay
8 Sep 2010 Reviewed Reviewer Report - Patrick Durez
8 Nov 2010 Author responded Author comments - Bart Van den Bemt
Resubmission - Version 2
8 Nov 2010 Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
17 Nov 2010 Reviewed Reviewer Report - Jozelio Carvalho
24 Nov 2010 Reviewed Reviewer Report - Cemalettin Aybay
12 Jan 2011 Author responded Author comments - Bart Van den Bemt
Resubmission - Version 4
12 Jan 2011 Submitted Manuscript version 4
Publishing
13 Jan 2011 Editorially accepted
13 Jan 2011 Article published 10.1186/1471-2474-12-12

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting info@biomedcentral.com.

You can find further information about the peer review system here.

Advertisement